Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Future Oncol
; 16(36): 3035-3043, 2020 Dec.
Article
in En
| MEDLINE
| ID: mdl-32902312
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Neoadjuvant Therapy
/
Squamous Cell Carcinoma of Head and Neck
/
Immune Checkpoint Inhibitors
/
Head and Neck Neoplasms
/
Neoplasm Recurrence, Local
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
Future Oncol
Year:
2020
Type:
Article
Affiliation country:
Germany